Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$11.35 - $16.73 $63,560 - $93,688
-5,600 Reduced 19.93%
22,500 $331,000
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $70,971 - $149,937
12,300 Added 77.85%
28,100 $338,000
Q3 2023

Nov 15, 2023

BUY
$6.27 - $8.15 $13,167 - $17,115
2,100 Added 15.33%
15,800 $100,000
Q2 2023

Aug 23, 2023

BUY
$6.63 - $9.9 $3,315 - $4,950
500 Added 3.79%
13,700 $107,000
Q1 2023

May 15, 2023

BUY
$5.72 - $7.91 $75,504 - $104,412
13,200 New
13,200 $89,000
Q2 2022

Aug 15, 2022

BUY
$3.37 - $7.55 $37,407 - $83,805
11,100 New
11,100 $48,000
Q3 2021

Nov 12, 2021

SELL
$2.28 - $2.95 $38,076 - $49,265
-16,700 Closed
0 $0
Q2 2021

Aug 06, 2021

BUY
$2.51 - $3.11 $8,785 - $10,885
3,500 Added 26.52%
16,700 $49,000
Q1 2021

May 14, 2021

BUY
$2.42 - $3.6 $31,944 - $47,520
13,200 New
13,200 $34,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $761M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.